Role of Surgery in Locally Recurrent and Metastatic Renal Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2019-10-17

AUTHORS

Andrew G. McIntosh , Eric C. Umbreit , Christopher G. Wood

ABSTRACT

Locally recurrent renal cell carcinoma following either partial or radical nephrectomy presents a complex set of technical and therapeutic challenges to clinicians. That there is a role for aggressive surgical resection in these clinical scenarios is clear. Retrospective evidence demonstrates the feasibility of salvage surgery and the potential benefit to oncologic outcomes. However, clear trade-offs exist between the possible oncologic benefits of surgical extirpation and the high-risk nature of salvage renal surgery. Similarly, local recurrence following primary ablative therapy can be challenging to diagnose on cross-sectional imaging, and salvage surgery is technically demanding. Verification of local recurrence in this situation is critical prior to embarking upon surgical intervention. Additionally, metastatic disease presents unique and complex challenges of its own. Metastasectomy has been demonstrated to have a role in the management of these patients but again must be undertaken with a clear understanding of the risks of surgery. Several retrospective series have demonstrated excellent survival in well-selected patients undergoing surgical management of metastatic disease. Broadly speaking, appropriate patient selection and risk evaluation are paramount to successful surgical management of both locally recurrent disease and metastatic disease. As the contemporary era of targeted therapy and immunotherapy continues to evolve, further evaluation of the role and timing of surgery will be necessary to infer meaningful standards of care. More... »

PAGES

295-305

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-030-24378-4_17

DOI

http://dx.doi.org/10.1007/978-3-030-24378-4_17

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1121855951


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McIntosh", 
        "givenName": "Andrew G.", 
        "id": "sg:person.011766030256.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011766030256.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Umbreit", 
        "givenName": "Eric C.", 
        "id": "sg:person.01061102240.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061102240.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2019-10-17", 
    "datePublishedReg": "2019-10-17", 
    "description": "Locally recurrent renal cell carcinoma following either partial or radical nephrectomy presents a complex set of technical and therapeutic challenges to clinicians. That there is a role for aggressive surgical resection in these clinical scenarios is clear. Retrospective evidence demonstrates the feasibility of salvage surgery and the potential benefit to oncologic outcomes. However, clear trade-offs exist between the possible oncologic benefits of surgical extirpation and the high-risk nature of salvage renal surgery. Similarly, local recurrence following primary ablative therapy can be challenging to diagnose on cross-sectional imaging, and salvage surgery is technically demanding. Verification of local recurrence in this situation is critical prior to embarking upon surgical intervention. Additionally, metastatic disease presents unique and complex challenges of its own. Metastasectomy has been demonstrated to have a role in the management of these patients but again must be undertaken with a clear understanding of the risks of surgery. Several retrospective series have demonstrated excellent survival in well-selected patients undergoing surgical management of metastatic disease. Broadly speaking, appropriate patient selection and risk evaluation are paramount to successful surgical management of both locally recurrent disease and metastatic disease. As the contemporary era of targeted therapy and immunotherapy continues to evolve, further evaluation of the role and timing of surgery will be necessary to infer meaningful standards of care.", 
    "editor": [
      {
        "familyName": "Libertino", 
        "givenName": "John A.", 
        "type": "Person"
      }, 
      {
        "familyName": "Gee", 
        "givenName": "Jason R.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-030-24378-4_17", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-030-24377-7", 
        "978-3-030-24378-4"
      ], 
      "name": "Renal Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "metastatic disease", 
      "salvage surgery", 
      "local recurrence", 
      "surgical management", 
      "recurrent renal cell carcinoma", 
      "aggressive surgical resection", 
      "role of surgery", 
      "metastatic renal cancer", 
      "appropriate patient selection", 
      "timing of surgery", 
      "risk of surgery", 
      "successful surgical management", 
      "renal cell carcinoma", 
      "cross-sectional imaging", 
      "high-risk nature", 
      "oncologic benefit", 
      "recurrent disease", 
      "surgical resection", 
      "oncologic outcomes", 
      "radical nephrectomy", 
      "therapeutic challenge", 
      "retrospective series", 
      "patient selection", 
      "surgical extirpation", 
      "surgical intervention", 
      "cell carcinoma", 
      "ablative therapy", 
      "renal surgery", 
      "Locally Recurrent", 
      "excellent survival", 
      "renal cancer", 
      "surgery", 
      "clinical scenarios", 
      "retrospective evidence", 
      "further evaluation", 
      "disease", 
      "patients", 
      "recurrence", 
      "therapy", 
      "potential benefits", 
      "metastasectomy", 
      "immunotherapy", 
      "nephrectomy", 
      "resection", 
      "carcinoma", 
      "risk evaluation", 
      "management", 
      "cancer", 
      "clinicians", 
      "recurrent", 
      "role", 
      "care", 
      "survival", 
      "outcomes", 
      "intervention", 
      "risk", 
      "evaluation", 
      "benefits", 
      "imaging", 
      "extirpation", 
      "clear understanding", 
      "evidence", 
      "contemporary era", 
      "timing", 
      "complex challenges", 
      "challenges", 
      "complex set", 
      "feasibility", 
      "standards", 
      "series", 
      "understanding", 
      "meaningful standards", 
      "era", 
      "selection", 
      "situation", 
      "nature", 
      "set", 
      "scenarios", 
      "verification"
    ], 
    "name": "Role of Surgery in Locally Recurrent and Metastatic Renal Cancer", 
    "pagination": "295-305", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1121855951"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-030-24378-4_17"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-030-24378-4_17", 
      "https://app.dimensions.ai/details/publication/pub.1121855951"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_136.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-030-24378-4_17"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-24378-4_17'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-24378-4_17'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-24378-4_17'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-24378-4_17'


 

This table displays all metadata directly associated to this object as RDF triples.

157 TRIPLES      22 PREDICATES      103 URIs      96 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-030-24378-4_17 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nd2c8adb083d641d599fb2ee70ce0dcf5
4 schema:datePublished 2019-10-17
5 schema:datePublishedReg 2019-10-17
6 schema:description Locally recurrent renal cell carcinoma following either partial or radical nephrectomy presents a complex set of technical and therapeutic challenges to clinicians. That there is a role for aggressive surgical resection in these clinical scenarios is clear. Retrospective evidence demonstrates the feasibility of salvage surgery and the potential benefit to oncologic outcomes. However, clear trade-offs exist between the possible oncologic benefits of surgical extirpation and the high-risk nature of salvage renal surgery. Similarly, local recurrence following primary ablative therapy can be challenging to diagnose on cross-sectional imaging, and salvage surgery is technically demanding. Verification of local recurrence in this situation is critical prior to embarking upon surgical intervention. Additionally, metastatic disease presents unique and complex challenges of its own. Metastasectomy has been demonstrated to have a role in the management of these patients but again must be undertaken with a clear understanding of the risks of surgery. Several retrospective series have demonstrated excellent survival in well-selected patients undergoing surgical management of metastatic disease. Broadly speaking, appropriate patient selection and risk evaluation are paramount to successful surgical management of both locally recurrent disease and metastatic disease. As the contemporary era of targeted therapy and immunotherapy continues to evolve, further evaluation of the role and timing of surgery will be necessary to infer meaningful standards of care.
7 schema:editor N43b65ba5cc634ebaafbbbdc0c432bc20
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N313e0003ad2b4cf2b908d16ff170e855
11 schema:keywords Locally Recurrent
12 ablative therapy
13 aggressive surgical resection
14 appropriate patient selection
15 benefits
16 cancer
17 carcinoma
18 care
19 cell carcinoma
20 challenges
21 clear understanding
22 clinical scenarios
23 clinicians
24 complex challenges
25 complex set
26 contemporary era
27 cross-sectional imaging
28 disease
29 era
30 evaluation
31 evidence
32 excellent survival
33 extirpation
34 feasibility
35 further evaluation
36 high-risk nature
37 imaging
38 immunotherapy
39 intervention
40 local recurrence
41 management
42 meaningful standards
43 metastasectomy
44 metastatic disease
45 metastatic renal cancer
46 nature
47 nephrectomy
48 oncologic benefit
49 oncologic outcomes
50 outcomes
51 patient selection
52 patients
53 potential benefits
54 radical nephrectomy
55 recurrence
56 recurrent
57 recurrent disease
58 recurrent renal cell carcinoma
59 renal cancer
60 renal cell carcinoma
61 renal surgery
62 resection
63 retrospective evidence
64 retrospective series
65 risk
66 risk evaluation
67 risk of surgery
68 role
69 role of surgery
70 salvage surgery
71 scenarios
72 selection
73 series
74 set
75 situation
76 standards
77 successful surgical management
78 surgery
79 surgical extirpation
80 surgical intervention
81 surgical management
82 surgical resection
83 survival
84 therapeutic challenge
85 therapy
86 timing
87 timing of surgery
88 understanding
89 verification
90 schema:name Role of Surgery in Locally Recurrent and Metastatic Renal Cancer
91 schema:pagination 295-305
92 schema:productId N8e15cd55faef47588c4b70c23a1534b2
93 N96e36abbddf24e318e62b4a2e1a3dc4c
94 schema:publisher N3d804dc8acb745ac8b3c19a82e71b8fc
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121855951
96 https://doi.org/10.1007/978-3-030-24378-4_17
97 schema:sdDatePublished 2022-10-01T06:52
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Nb480bada2faf4cf094c9bc5028a7ba73
100 schema:url https://doi.org/10.1007/978-3-030-24378-4_17
101 sgo:license sg:explorer/license/
102 sgo:sdDataset chapters
103 rdf:type schema:Chapter
104 N1f033f1b36c140548e20eff25897330c rdf:first sg:person.01040121722.56
105 rdf:rest rdf:nil
106 N1feec5ac49484f0bb606ac3e04898c9d rdf:first N320b8980e311472c8b1d024256254964
107 rdf:rest rdf:nil
108 N313e0003ad2b4cf2b908d16ff170e855 schema:isbn 978-3-030-24377-7
109 978-3-030-24378-4
110 schema:name Renal Cancer
111 rdf:type schema:Book
112 N320b8980e311472c8b1d024256254964 schema:familyName Gee
113 schema:givenName Jason R.
114 rdf:type schema:Person
115 N3d804dc8acb745ac8b3c19a82e71b8fc schema:name Springer Nature
116 rdf:type schema:Organisation
117 N43b65ba5cc634ebaafbbbdc0c432bc20 rdf:first Nedd3afe4dec241e5924a178366aa9c9a
118 rdf:rest N1feec5ac49484f0bb606ac3e04898c9d
119 N8dbf3cdd165e4d5e85c09f26e9db941f rdf:first sg:person.01061102240.08
120 rdf:rest N1f033f1b36c140548e20eff25897330c
121 N8e15cd55faef47588c4b70c23a1534b2 schema:name dimensions_id
122 schema:value pub.1121855951
123 rdf:type schema:PropertyValue
124 N96e36abbddf24e318e62b4a2e1a3dc4c schema:name doi
125 schema:value 10.1007/978-3-030-24378-4_17
126 rdf:type schema:PropertyValue
127 Nb480bada2faf4cf094c9bc5028a7ba73 schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 Nd2c8adb083d641d599fb2ee70ce0dcf5 rdf:first sg:person.011766030256.13
130 rdf:rest N8dbf3cdd165e4d5e85c09f26e9db941f
131 Nedd3afe4dec241e5924a178366aa9c9a schema:familyName Libertino
132 schema:givenName John A.
133 rdf:type schema:Person
134 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
135 schema:name Medical and Health Sciences
136 rdf:type schema:DefinedTerm
137 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
138 schema:name Oncology and Carcinogenesis
139 rdf:type schema:DefinedTerm
140 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
141 schema:familyName Wood
142 schema:givenName Christopher G.
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
144 rdf:type schema:Person
145 sg:person.01061102240.08 schema:affiliation grid-institutes:grid.240145.6
146 schema:familyName Umbreit
147 schema:givenName Eric C.
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061102240.08
149 rdf:type schema:Person
150 sg:person.011766030256.13 schema:affiliation grid-institutes:grid.240145.6
151 schema:familyName McIntosh
152 schema:givenName Andrew G.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011766030256.13
154 rdf:type schema:Person
155 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
156 schema:name Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
157 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...